source
- Belgian startup Armed Cell Therapeutics acquires Galapagos-derived CAR-T assets for €8 million upfrontArmed Cell Therapeutics, a new Belgian biotech chaired by former Galapagos CEO Paul Stoffels, has taken ownership of several cell therapy programs previously held by Lakefront Biotherapeutics. The…
- OrbiMed secures $3 billion for new life science funds, with over $1 billion earmarked for AsiaOrbiMed, a leading global investor in life science companies, announced the closing of two new funds that together total about $3 billion. The capital will be deployed across a range of private equ…